索托拉西布在KRAS G12C突变转移性非小细胞肺癌患者中的真实世界有效性与耐受性:IFCT-2102 Lung KG12Ci研究
这项法国回顾性多中心研究分析了458例接受索托拉西布治疗的KRAS G12C突变非小细胞肺癌患者,中位真实世界无进展生存期3.5个月,总生存期8.3个月,客观缓解率33.2%,3-4级肝毒性相关不良事件发生率5.2%,16.5%因毒性停药。
要点
- 中位真实世界无进展生存期3.5个月,总生存期8.3个月
- 真实世界客观缓解率33.2%,疾病控制率63.2%
- 3-4级肝毒性相关不良事件发生率5.2%,16.5%因毒性停药
核心结论
- 该研究提供了索托拉西布在晚期或转移性KRAS G12C突变非鳞状非小细胞肺癌真实世界中的有效性和安全性信息。
研究设计与样本
- 法国回顾性多中心研究,分析早期访问计划中接受至少一剂索托拉西布的NSCLC患者,共纳入来自76个中心的458例患者,中位年龄65.8岁。
主要发现
- 中位真实世界无进展生存期为3.5个月(95%CI 3.1-4.2),中位真实世界总生存期为8.3个月(95%CI 7.5-9.3)。
- 真实世界客观缓解率为33.2%,疾病控制率为63.2%。
- 脑转移患者的颅内真实世界客观缓解率为20.1%,颅内疾病控制率为66.9%。
- 肝毒性相关的3-4级不良事件发生于5.2%的患者,16.5%的患者因毒性停用索托拉西布。
- 患者中43.4%为女性,28.3%体能状态评分≥2,95.4%为现吸烟或既往吸烟者,38.0%有脑转移且其中55.2%在索托拉西布启动时处于进展状态;PD-L1表达<1%、≥1-49%、≥50%和未知分别占35.1%、34.1%、23.4%和7.4%;96.7%接受过既往治疗,包括免疫治疗(54.9%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Sotorasib has shown efficacy in a phase 3 trial compared to docetaxel among previously treated non-small cell lung cancer (NSCLC) patients with a KRAS G12C mutation. However, its real-world effectiveness and tolerance, especially post-immunotherapy, remain debated. METHODS: This French retrospective multicentre study analysed NSCLC patients receiving at least one dose of sotorasib as part of early access program The main objective was to assess real-world progression-free survival (rwPFS), and secondary objectives included assessment of overall survival (rwOS) and sotorasib-related hepatotoxicity. RESULTS: 458 patients from 76 centres were analysed, with a median age 65.8. Among them, 43.4 % were female, 28.3 % had performance status ≥ 2, 95.4 % were active/former smokers, and 38.0 % had brain metastases with 55.2 % in progression at sotorasib initiation. PD-L1 expression was < 1 %, ≥ 1-49 %, ≥ 50 %, and unknown in 35.1 %, 34.1 %, 23.4 %, and 7.4 % of patients, respectively. Most patients had received prior treatments (96.7 %), including immunotherapy (54.9 %). Median (95 % confidence interval [CI]) rwPFS and rwOS were 3.5 (3.1-4.2) and 8.3 (7.5-9.3) months, with a median (95 % CI) follow-up of 15.8 (13.9-17.3) and 16.4 (15.5-17.3) months, respectively. The real-world objective response rate (rwORR) was 33.2 % and disease control rate (rwDCR) was 63.2 %. In patients with brain metastases, cerebral rwORR and rwDCR were 20.1 % and 66.9 %, respectively. Grade 3-4 adverse events related to hepatotoxicity occurred in 5.2 % of patients. Sotorasib was discontinued for toxicity in 16.5 % of patients. CONCLUSION: This study gave insights into effectiveness and safety of sotorasib in a real-world setting, in advanced or metastatic KRAS G12C-mutated non-squamous NSCLC.
引用
- Wislez M, Mascaux C, Cadranel J, et al. Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study. Eur J Cancer. 2025. PMID: 39970524. doi:10.1016/j.ejca.2025.115301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。